09-03-2017
In the context of the commemorative session of the 40th anniversary of Chemistry at NOVA University, one of the lectures will be dedicated to the important relationship between Fundamental Research, Clinical Practice and the Biopharmaceutical Industry. The speaker will be Professor Chris Lowe of the University of Cambridge, whose work in fundamental and applied science was the basis for the creation of 10 technology-based companies. Professor Chris Lowe has received numerous national and international distinctions, including the distinction "Order of the British Empire" in 2010.
Professor Chris Lowe will speak in his experience as director of the Cambridge Academy of Therapeutic Sciences (CATS), an initiative that harmonizes and promotes the relationship between fundamental and applied health science through the involvement of research entities, hospitals, companies and regulatory agents.
The conference of Professor Chris Lowe is part of the program of the commemorative session of the 40th anniversary of NOVA Chemistry, which will take place on March 29, 2017, at the Grand Auditorium of FCT NOVA, beginning at 14H15. The session is open to the public.
Professor Christopher R. Lowe is in the Institute of Biotechnology at the Department of Chemical Engineering & Biotechnology at the University of Cambridge and researches in both diagnostics and therapeutics in the healthcare biotechnology sector. He is a fellow of the Royal Academy of Engineering, the Institute of Physics and the Royal Society of Chemistry. He has 380 peer-reviewed publications, 8 books and monographs, >100 patents and has supervised >95 PhD students and has a number of national and international prizes: “Queen’s Award for Technological Achievement”; “Queen’s Anniversary Prize for Higher and Further Education”; “Most Entrepreneurial Scientist of the UK”; OBE in the Queen’s New Year Honours; BBSRC Commercial Innovator of the Year in 2011. He has been the driving force for the establishment of 11 spin-out companies including ProMetic Biosciences Inc (Market Cap $1.9-2.1B), Cambridge Sensors Ltd and Psynova Neurotech Ltd and Royale Therapeutics Ltd., has a number of directorships and fosters entrepreneurship within the University via a Master’s in Bioscience Enterprise, the University’s Seed Fund Committee and other Business School and student-led activities. He is active in various government committees and in a number of legal and entrepreneurial roles.His group's primary research interest is in healthcare biotechnology, particularly where it is applied to the biopharmaceutical, sensors and diagnostics and enzyme and microbial technology sectors. The work is highly multidisciplinary and not only covers aspects of molecular biology, biochemistry, microbiology, chemistry, physics, electronics and engineering, but also the entire range from fundamental science to strategic and applied science. He is currently Director of the newly established Cambridge Academy of Therapeutic Sciences (CATS) within the University of Cambridge.
